tbuckley/cabot-search huggingface dataset:
Secondary acute myeloid leukemia following treatment with epipodophyllotoxins.
Authors: S B Murphy
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.2.199 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8426194 Secondary acute myeloid leukemia following treatment with epipodophyllotoxins. S B MurphyxS B MurphySearch for articles by this author https://doi.org/10.1200/JCO.1993.11.2.199 First Page PDF © 1993 by American Society of Clinical Oncology
A Surgical Safety Checklist
Authors: David C Levin
Journal: New England Journal of Medicine (2009)

observed no such age-dependent decrease in GFR (Fig. 1).Our results show a decrease in GFR (as estimated with the use of the Modification of Diet in Renal Disease [MDRD] formula) after donation in all three age groups but with stable kidney function over the years.Our findings support the conclusions of Ibrahim et al. and also indicate that kidney donation by older donors may be considered relatively safe over time, since kidney function does not appear to decline progressively.
Drug-induced rapid cycling: possible outcomes and management
Authors: G Oppenheim
Journal: American Journal of Psychiatry (1982)

Rapid cycling of mood change induced by antidepressant drugs has recently emerged as a significant diagnostic and therapeutic problem. The author describes two additional cases. Cessation of treatment with the offending drug may leave the patient depressed, manic, or euthymic or in a state of continued rapid cycling. The author suggests an approach to management of this condition.
Neural Mechanisms of Hierarchical Planning in a Virtual Subway Network
Authors: Jan Balaguer, Hugo Spiers, Demis Hassabis, Christopher Summerfield
Journal: Neuron (2016)

Planning allows actions to be structured in pursuit of a future goal. However, in natural environments, planning over multiple possible future states incurs prohibitive computational costs. To represent plans efficiently, states can be clustered hierarchically into "contexts". For example, representing a journey through a subway network as a succession of individual states (stations) is more costly than encoding a sequence of contexts (lines) and context switches (line changes). Here, using functional brain imaging, we asked humans to perform a planning task in a virtual subway network. Behavioral analyses revealed that humans executed a hierarchically organized plan. Brain activity in the dorsomedial prefrontal cortex and premotor cortex scaled with the cost of hierarchical plan representation and unique neural signals in these regions signaled contexts and context switches. These results suggest that humans represent hierarchical plans using a network of caudal prefrontal structures.Video AbstracteyJraWQiOiI4ZjUxYWNhY2IzYjhiNjNlNzFlYmIzYWFmYTU5NmZmYyIsImFsZyI6IlJTMjU2In0.eyJzdWIiOiI2NmE3ZDk4MjJiYWUxOGE1NDNiYWE3OWUxMTdkNWJkNiIsImtpZCI6IjhmNTFhY2FjYjNiOGI2M2U3MWViYjNhYWZhNTk2ZmZjIiwiZXhwIjoxNjc5MTgzNTQ2fQ.Itg6vZn7KVhvY80-lmeL299ktOZTe-ShamCfY0gzBR6D7Hk5RINXOYhYfSgufbaAo2psYFW24DuG7Y_jgxrlSaEhP6M-kz_gIoVL86v8TxVluUjiSDlbih4yEyu4HAwl-kPAZdlk3c2AeKy-ae1oWwi7VRbKSEj_aNJl1OMniDVd1q_xg59JDFik7scG8h1ymQjNrQr6tXiwMeqoVc9ICYcfPEW0ztC-_2LGk3432tP1YIxqU4BGYQ-sJ-8DSKQtL4YIjjm3n9p-Aqew1P-moQDVg-SYlqMuTYxSn_SrAV3RktbiOGZMbtxgScNfLnqkWeRf2EGL80oQbxjSzEUZyw(mp4, (51.46 MB) Download video
Assessment of Aggressiveness of Breast Cancer Using Simultaneous 18F-FDG-PET and DCE-MRI
Authors: Nathaniel E. Margolis, Linda Moy, Eric E. Sigmund, Melanie Freed, Jason McKellop, Amy N. Melsaether, Sungheon Gene Kim
Journal: Clinical Nuclear Medicine (2016)

This study aims to investigate the feasibility of using simultaneous breast MRI and PET to assess the synergy of MR pharmacokinetic and fluorine-18 fluorodeoxyglucose (F-FDG) uptake data to characterize tumor aggressiveness in terms of metastatic burden and Ki67 status.Twelve consecutive patients underwent breast and whole-body PET/MRI. During the MR scan, PET events were simultaneously accumulated. MR contrast kinetic model parametric maps were computed using the extended Tofts model, including the volume transfer constant between blood plasma and the interstitial space (K), the transfer constant from the interstitial space to the blood plasma (kep), and the plasmatic volume fraction (Vp).Patients with systemic metastases had a significantly lower kep compared to those with local disease (0.45 vs. 0.99 min, P = 0.011). Metastatic burden correlated positively with K and standardized uptake value (SUV), and negatively with kep. Ki67 positive tumors had a significantly greater K compared to Ki67 negative tumors (0.29 vs. 0.45 min, P = 0.03). A negative correlation was found between metabolic tumor volume and transfer constant (K or Kep).These preliminary results suggest that MR pharmacokinetic parameters and FDG-PET may aid in the assessment of tumor aggressiveness and metastatic potential. Future studies are warranted with a larger cohort to further assess the role of pharmacokinetic modeling in simultaneous PET/MRI imaging.
A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults
Authors: P H Wender, F W Reimherr, D Wood, M Ward
Journal: American Journal of Psychiatry (1985)

Thirty-seven adult patients meeting the Utah criteria for attention deficit disorder, residual type, were entered into a double-blind crossover trial of methylphenidate and placebo. A moderate-to-marked therapeutic response occurred in 21 (57%) of the patients while receiving methylphenidate and in four (11%) while receiving placebo, a highly significant difference statistically and clinically. The responding patients showed significant improvement in the following areas: attentional difficulty, motor overactivity, affective lability, and impulsivity. The diagnosis of attention deficit disorder, residual type, should be considered in patients with prominent complaints of impulsivity, restlessness, emotional lability, and hot temper who do not suffer from schizophrenia or major mood disorder and do not have symptoms of schizotypal or borderline personality disorders.
Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD
Authors: Ruben Poesen, Kathleen Claes, Pieter Evenepoel, Henriette de Loor, Patrick Augustijns, Dirk Kuypers, Björn Meijers
Journal: Journal of the American Society of Nephrology (2016)

Colonic microbial metabolism substantially contributes to uremic solute production. p -Cresyl sulfate and indoxyl sulfate are the main representatives of solutes of microbial origin and also, protein-bound solutes, exhibiting high protein-binding affinity and dependence on tubular secretion. Phenylacetylglutamine is another microbial metabolite with high dependence on tubular secretion but low protein-binding affinity. The relevance of such solutes is unknown. Therefore, we prospectively followed 488 patients with CKD stages 1–5 and a measurement of serum phenylacetylglutamine by liquid chromatography-mass spectrometry. In a subgroup, we determined 24-hour urinary excretion as a surrogate of intestinal uptake as well as renal clearance of phenylacetylglutamine. We performed outcome analysis for mortality (51 events) and cardiovascular disease (75 events). Serum phenylacetylglutamine level correlated with 24-hour urinary excretion (rho=0.55; P &lt;0.001) and clearance of phenylacetylglutamine (rho=−0.76; P &lt;0.001). Phenylacetylglutamine clearance also correlated with eGFR (rho=0.84; P &lt;0.001). Furthermore, serum phenylacetylglutamine level associated with mortality (hazard ratio per 1-SD increase, 1.77; 95% confidence interval, 1.22 to 2.57; P =0.003) and cardiovascular disease (hazard ratio, 1.79; 95% confidence interval, 1.32 to 2.41; P &lt;0.001) after adjustment for age, sex, presence of diabetes mellitus, prior cardiovascular disease, and eGFR. Thus, serum phenylacetylglutamine level is elevated in patients with more advanced CKD and determined by intestinal uptake and renal clearance, and it is not fully accounted for by differences in eGFR. High serum phenylacetylglutamine level is a strong and independent risk factor for mortality and cardiovascular disease, suggesting the relevance of microbial metabolism and/or tubular dysfunction in CKD, irrespective of protein binding.
Drugs and the DST: need for a reappraisal
Authors: R P Kraus, P Grof, G M Brown
Journal: American Journal of Psychiatry (1988)

It has generally been assumed that psychotropic drugs do not influence results on the dexamethasone suppression test (DST), except in some specific situations. Yet they directly affect the activity of many neurotransmitter systems, which in turn regulate hypothalamic-pituitary-adrenal (HPA) axis functioning. Several reports have shown correlations between the intake of or recent withdrawal from psychoactive substances and changes in DST results. A review of the DST literature reveals that these effects have not been controlled in most DST studies. It is therefore possible that the consequences of intake of psychotropic agents may have contributed to the debate surrounding the DST by producing unappreciated spurious DST results.
Epidemic diffusion of KPC carbapenemase-producing Klebsiella pneumoniae in Italy: results of the first countrywide survey, 15 May to 30 June 2011
Authors: T Giani, B Pini, F Arena, V Conte, S Bracco, R Migliavacca, Collective the AMCLI-CRE Survey Participants, A Pantosti, L Pagani, F Luzzaro, G M Rossolini
Journal: Eurosurveillance (2013)

Carbapenem-resistant Enterobacteriaceae (CRE) are emerging as a public health problem in various settings. In Italy, a rapid and remarkable increase of carbapenem-non-susceptible Klebsiella pneumoniae has been reported since 2010. Here we report on the results of a countrywide cross-sectional survey, carried out from 15 May to 30 June 2011 to investigate the diffusion of CRE in Italy and to characterise the most prevalent resistance mechanisms and their dissemination patterns. CRE were reported from most (23 of 25) participating laboratories, with an overall proportion of 3.5% and 0.3% among consecutive non-duplicate clinical isolates of Enterobacteriaceae from inpatients (n=7,154) and outpatients (n=6,595), respectively. K. pneumoniae was the most frequent species (proportion of carbapenem-non-susceptible isolates: 11.9%), while a minority of CRE of other species were detected. Carbapenemase production was detected in the majority (85%) of CRE. KPC-type enzymes were by far the most common (89.5% of carbapenemase producers), followed by VIM-1 (9.2%) and OXA-48 (1.3%). KPC-producing K. pneumoniae (KPC-KP) were detected in most centres and contributed majorly to the epidemic dissemination of CRE recently observed in our country. Dissemination of KPC-KP was mostly sustained by strains of clonal complex 258 (ST-258 producing KPC-2 or KPC-3, and ST-512 producing KPC-3), while a minority belonged to ST-101.
Will Physicians Lead on Controlling Health Care Costs?
Authors: Ezekiel J. Emanuel, Andrew Steinmetz
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
10,11-Methylenedioxycamptothecin, a Topoisomerase I Inhibitor of Increased Potency: DNA Damage and Correlation to Cytotoxicity in Human Colon Carcinoma (HT-29) Cells
Authors: P M O'Connor, D Kerrigan, R Bertrand, K W Kohn, Y Pommier
Journal: Cancer Communications (1990)

We had previously shown that 10,11-methylenedioxy-20-(RS)-camptothecin (MDO-CPT) is a more potent inhibitor of purified DNA topoisomerase I than 20-(S)-camptothecin (CPT). The current studies compared the cytotoxicity and DNA damage induced by MDO-CPT and CPT in the human colon carcinoma cell line, HT-29. MDO-CPT was 7- to 10-fold more potent than CPT both for cytotoxicity (ID50 = 25 vs. 180 nM) and production of DNA single-strand breaks (SSB). Kinetics of SSB formation and reversal were similar for MDO-CPT and CPT. DNA-protein crosslinks (DPC) were also produced by both drugs with a SSB/DPC ratio of 1/1. Moreover, no SSB were detected under non-deproteinizing conditions, indicating that both CPT and MDO-CPT produced protein-linked DNA single-strand breaks. A good correlation between cytotoxic potency and protein-linked DNA single-strand break production was observed for CPT and MDO-CPT, implying a causal relationship between drug-induced cytotoxicity and topoisomerase I inhibition. The sensitivity of human colon HT-29 cancer cells to camptothecins may be a selective phenomenon since these cells normally express natural resistance to current chemotherapeutic drugs, including topoisomerase II inhibitors.
Abstract P1-16-08: Inhibition of β-catenin pathway to overcome endocrine resistance in breast cancer
Authors: HS Won, KE Lee, KM Lee, EM Nam, Y-C Mun, C-M Seong, SN Lee
Journal: Cancer Research (2016)

Abstract Background: It is well known that Wnt/β-catenin signaling pathway is involved in hormone receptor negative breast cancer, especially triple-negative breast cancer. In the case of hormone resistant breast cancer cells, they rarely showed hormone receptor expression. So we aimed to investigate whether the β-catenin pathway becomes activated in endocrine-resistant breast cancer cells and inhibition of β-catenin pathway can overcome endocrine resistance. Methods: We have established an MCF-7-derived tamoxifen-resistant cell line (TamR) by long-term culture of MCF-7 cells with gradually increasing 4-hydroxytamoxifen concentration till 3μM. The levels of protein expression and mRNA transcripts were determined using western blot analysis and real-time quantitative PCR. The transcriptional activity of β-catenin was measured using luciferase activity assay. We used ICG-001 as inhibitor of β-catenin transcription activity. Results: The expression of estrogen receptor was significantly decreased in TamR cells. On the other hand, the expressions of HER2 and EGFR were increased in TamR cells than in control cells. The active (uncomplexed form) β-catenin level was increased in TamR cells, and also showed a significantly increased β-catenin transcriptional activity. The ICG-001, small-molecular inhibitor of Wnt/β-catenin pathway, treatment significantly reduced β-catenin transcriptional activity in TamR cells. The ICG-001 reduced cell viability fo TamR cells which showed resistance to tamoxifen by 65.3%, and also inhibited target gene cyclin D1 expression. The combination of ICG-001 and mTOR inhibitor, rapamycin reduced cell viability of TamR cells by 81.7% and there was an additive effect of two drugs as a combination index of 1.022. Conclusions: The β-catenin pathway is activated in endocrine-resistant breast cancer cells and inhibition of that pathway would be a new therapeutic strategy which overcomes endocrine resistance in breast cancer. Citation Format: Won HS, Lee KE, Lee KM, Nam EM, Mun Y-C, Seong C-M, Lee SN. Inhibition of β-catenin pathway to overcome endocrine resistance in breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-16-08.
Follow-up and family study of anxious depression
Authors: P J Clayton, W M Grove, W Coryell, M Keller, R Hirschfeld, J Fawcett
Journal: American Journal of Psychiatry (1991)

The failure of the concept of anxious depression to find its way into DSM-III-R led the authors to conclude that a further report on the occurrence of anxiety symptoms in depressed subjects is indicated.The subjects were 327 consecutively evaluated inpatients and outpatients with primary unipolar depressive disorder at five university medical centers participating in the National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. The authors restricted their sample selection to patients with primary depressive disorder so that patients with other preexisting psychiatric disorders, especially anxiety disorders, would not contaminate the symptom picture, family studies, or follow-up. The examined six anxiety symptoms and derived a new anxiety summary score to show the effect of anxiety in depression on family data and 5-year outcome.Depressed subjects with higher ratings for anxiety took longer to recover. There was also a significant relationship between anxiety in depressed probands and the risk for primary unipolar depressive disorder, but not anxiety disorders or alcoholism, among 832 blindly interviewed first-degree relatives.These data confirm the usefulness of subdividing depressed patients according to anxiety symptoms: psychic and somatic symptoms of anxiety, taken together, significantly predict family illness and course. The data also emphasize the wisdom of requiring that generalized anxiety disorder not be diagnosed in the presence of a mood disorder. Clearly, symptoms of anxiety coexist with depression and need to be recognized for the effective treatment of the underlying depressive disorder.
Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis
Authors: Yan Wang, Sushil Kumar, Satyanarayana Rachagani, Balasrinivasa R. Sajja, Ying Xie, Yu Hang, Maneesh Jain, Jing Li, Michael D. Boska, Surinder K. Batra, David Oupický
Journal: Biomaterials (2016)
Airway hyperresponsiveness in chronic obstructive pulmonary disease: A marker of asthma-chronic obstructive pulmonary disease overlap syndrome?
Authors: Ruzena Tkacova, Darlene L.Y. Dai, Judith M. Vonk, Janice M. Leung, Pieter S. Hiemstra, Maarten van den Berge, Lisette Kunz, Zsuzsanna Hollander, Donald Tashkin, Robert Wise, John Connett, Raymond Ng, Bruce McManus, S.F. Paul Man, Dirkje S. Postma, Don D. Sin
Journal: Journal of Allergy and Clinical Immunology (2016)
The Influence of Chemotherapy-Induced Leucopenia (Cil) During Preoperative Chemotherapy (Pre-Cx) on Survival in Esophageal Squamous Cell Carcinoma (Escc) from the Results of Jcog9907
Authors: H. Hara, N. Ando, H. Igaki, M. Shinoda, K. Kato, Y. Kitagawa, J. Mizusawa, K. Nakamura
Journal: Annals of Oncology (2014)
Long-term computed tomographic changes in cystic fibrosis patients treated with ivacaftor
Authors: Guillaume Chassagnon, Dominique Hubert, Isabelle Fajac, Pierre-Régis Burgel, Marie-Pierre Revel
Journal: European Respiratory Journal (2016)

Cystic fibrosis (CF) patients with gating mutations in the gene coding for the CF transmembrane conductance regulator (CFTR) protein have been the first to benefit from CFTR-targeted therapies since the approval of ivacaftor in 2012 by the Food and Drug Administration and the European Medicines Agency. Ivacaftor is a potentiator that increases chloride transport through the defective CFTR protein [1, 2]. In phase III clinical trials, ivacaftor significantly improved lung function and clinical status in patients with a G551D mutation aged ≥6 years [3, 4]. In the two studies conducted in adults and children, the forced expiratory volume in 1 s (FEV1) showed a 10.4% predicted and 12.5% pred point increase from baseline after 24 weeks of treatment, as compared to a 0.1 and 0.2% pred point decrease in the control group. Clinical efficacy of ivacaftor was also shown in patients with other gating mutations of the CFTR gene, with a 7.5% pred point increase in FEV1 after 8 weeks of treatment [5]. In all these phase III studies, the primary endpoint was the change in FEV1 and secondary endpoints were other clinical and functional parameters, such as change in weight, respiratory exacerbation rate, health status, and sweat-chloride concentration. Imaging was never listed as an endpoint. Data on computed tomography (CT) changes upon ivacaftor treatment are scarce [6–8] and long-term changes remain unknown. The aim of this study was to assess short- and long-term CT changes in adult CF patients treated with ivacaftor. In CF patients treated with ivacaftor, improvement of CT abnormalities remains stable on long-term follow-up <http://ow.ly/Zxu2B> The investigators are: Isabelle Danner-Boucher (Pulmonary Dept, G&R Laënnec Hospital, Nantes, France), Benoît Desrues (Pulmonary Dept, Pontchaillou Hospital, Rennes, France), Stéphane Dominique (Pulmonary Dept, Charles Nicolle Hospital, Rouen, France), Isabelle Durieu (Dept of Internal Medicine, Hospices Civils de Lyon et Université Claude Bernard Lyon1, Pierre-Bénite, France), Dominique Grenet (Pulmonary Dept, Foch Hospital, Suresnes, France), Anne-Cécile Henriet (Pulmonary Dept, Bretonneau Hospital, Tours, France), Anne Prevotat (Pulmonary Dept, Calmette Hospital, Lille, France).
Reply to Dino Papeš, Ana Jerončić's Letter to the Editor re: Giuseppe Magistro, Florian M.E. Wagenlehner, Magnus Grabe, Wolfgang Weidner, Christian G. Stief, J. Curtis Nickel. Contemporary Management of Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Eur Urol 2016;69:286–97
Authors: Giuseppe Magistro, Florian M.E. Wagenlehner, J. Curtis Nickel
Journal: European Urology (2016)
Breast Cancer Risk From Modifiable and Nonmodifiable Risk Factors Among White Women in the United States
Authors: Paige Maas, Myrto Barrdahl, Amit D. Joshi, Paul L. Auer, Mia M. Gaudet, Roger L. Milne, Fredrick R. Schumacher, William F. Anderson, David Check, Subham Chattopadhyay, Laura Baglietto, Christine D. Berg, Stephen J. Chanock, David G. Cox, Jonine D. Figueroa, Mitchell H. Gail, Barry I. Graubard, Christopher A. Haiman, Susan E. Hankinson, Robert N. Hoover, Claudine Isaacs, Laurence N. Kolonel, Loic Le Marchand, I-Min Lee, Sara Lindström, Kim Overvad, Isabelle Romieu, Maria-Jose Sanchez, Melissa C. Southey, Daniel O. Stram, Rosario Tumino, Tyler J. VanderWeele, Walter C. Willett, Shumin Zhang, Julie E. Buring, Federico Canzian, Susan M. Gapstur, Brian E. Henderson, David J. Hunter, Graham G Giles, Ross L. Prentice, Regina G. Ziegler, Peter Kraft, Montse Garcia-Closas, Nilanjan Chatterjee
Journal: JAMA Oncology (2016)

An improved model for risk stratification can be useful for guiding public health strategies of breast cancer prevention.